• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    9/2/25 9:04:47 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email
    pm-20250902
    0001413329false00014133292025-09-022025-09-020001413329us-gaap:CommonStockMember2025-09-022025-09-020001413329pm:A2.750Notesdue2026Member2025-09-022025-09-020001413329pm:A2.875Notesdue2026Member2025-09-022025-09-020001413329pm:A0.125Notesdue2026Member2025-09-022025-09-020001413329pm:A3.125Notesdue2027Member2025-09-022025-09-020001413329pm:A3.125Notesdue2028Member2025-09-022025-09-020001413329pm:A2.875Notesdue2029Member2025-09-022025-09-020001413329pm:A3.375NotesDue2029Member2025-09-022025-09-020001413329pm:A2.750NotesDue2029Member2025-09-022025-09-020001413329pm:A3.750NotesDue2031Member2025-09-022025-09-020001413329pm:A0.800Notesdue2031Member2025-09-022025-09-020001413329pm:A3.250NotesDue2032Member2025-09-022025-09-020001413329pm:A3.125Notesdue2033Member2025-09-022025-09-020001413329pm:A2.000Notesdue2036Member2025-09-022025-09-020001413329pm:A1.875Notesdue2037Member2025-09-022025-09-020001413329pm:A6.375Notesdue2038Member2025-09-022025-09-020001413329pm:A1.450Notesdue2039Member2025-09-022025-09-020001413329pm:A4.375Notesdue2041Member2025-09-022025-09-020001413329pm:A4.500Notesdue2042Member2025-09-022025-09-020001413329pm:A3.875Notesdue2042Member2025-09-022025-09-020001413329pm:A4.125Notesdue2043Member2025-09-022025-09-020001413329pm:A4.875Notesdue2043Member2025-09-022025-09-020001413329pm:A4.250Notesdue2044Member2025-09-022025-09-02

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    FORM 8-K



    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of
    The Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): September 2, 2025



    Philip Morris International Inc.
    (Exact name of registrant as specified in its charter)

    Virginia
    1-33708
    13-3435103
    (State or other jurisdiction
    of incorporation)
    (Commission File Number)
    (I.R.S. Employer
    Identification No.)

    677 Washington Blvd, Ste. 1100StamfordConnecticut06901
    (Address of principal executive offices)(Zip Code)


    Registrant's telephone number, including area code: (203) 905-2410
    (Former name or former address, if changed since last report.)



    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:




    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




    Securities registered pursuant to Section 12(b) of the Act:

    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, no par valuePMNew York Stock Exchange
    2.750% Notes due 2026PM26ANew York Stock Exchange
    2.875% Notes due 2026PM26New York Stock Exchange
    0.125% Notes due 2026PM26BNew York Stock Exchange
    3.125% Notes due 2027PM27New York Stock Exchange
    3.125% Notes due 2028PM28New York Stock Exchange
    2.875% Notes due 2029PM29New York Stock Exchange
    3.375% Notes due 2029PM29ANew York Stock Exchange
    2.750% Notes due 2029PM29DNew York Stock Exchange
    3.750% Notes due 2031PM31BNew York Stock Exchange
    0.800% Notes due 2031PM31New York Stock Exchange
    3.250% Notes due 2032PM32New York Stock Exchange
    3.125% Notes due 2033PM33New York Stock Exchange
    2.000% Notes due 2036PM36New York Stock Exchange
    1.875% Notes due 2037PM37ANew York Stock Exchange
    6.375% Notes due 2038PM38New York Stock Exchange
    1.450% Notes due 2039PM39New York Stock Exchange
    4.375% Notes due 2041PM41New York Stock Exchange
    4.500% Notes due 2042PM42New York Stock Exchange
    3.875% Notes due 2042PM42ANew York Stock Exchange
    4.125% Notes due 2043PM43New York Stock Exchange
    4.875% Notes due 2043PM43ANew York Stock Exchange
    4.250% Notes due 2044PM44New York Stock Exchange











    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
                                                    
             Emerging growth company
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
    ☐




    Item 7.01.Regulation FD Disclosure.

    On September 2, 2025, Philip Morris International Inc. (“PMI”) is hosting a live audio webcast of a presentation and question-and-answer session by PMI’s Chief Executive Officer, Jacek Olczak, at the Barclays Global Consumer Staples Conference. In connection with the webcast, PMI is furnishing to the Securities and Exchange Commission the press release attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference to this Item 7.01.

    In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report on Form 8-K shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as may be expressly set forth by specific reference in such filing or document.



    Item 9.01.Financial Statements and Exhibits.


    (d)Exhibits.

    99.1
    Philip Morris International Inc. Press Release, dated September 2, 2025 (furnished pursuant to Item 7.01).

    104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document and contained in Exhibit 101)





    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    PHILIP MORRIS INTERNATIONAL INC.
    By:/s/ DARLENE QUASHIE HENRY
    Name:Darlene Quashie Henry
    Title:Vice President, Associate General Counsel & Corporate Secretary
    Date: September 2, 2025


    Get the next $PM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    7/9/2025$220.00Buy
    Jefferies
    5/22/2025$195.00Buy
    Needham
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    1/23/2024$105.00 → $86.50Buy → Sell
    UBS
    More analyst ratings

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Philip Morris International with a new price target

    Jefferies resumed coverage of Philip Morris International with a rating of Buy and set a new price target of $220.00

    7/9/25 8:31:10 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Needham initiated coverage on Philip Morris International with a new price target

    Needham initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $195.00

    5/22/25 8:27:06 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International upgraded by UBS with a new price target

    UBS upgraded Philip Morris International from Sell to Neutral and set a new price target of $170.00

    4/25/25 8:25:28 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Defiance Launches ZYN: 2X Long ETF for Philip Morris International Inc.

    MIAMI, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced the launch of the Defiance Daily Target 2X Long PM ETF (Ticker: ZYN). This fund provides investors with amplified 2X daily exposure to the performance of Philip Morris International Inc. (NYSE:PM), enabling retail investors to participate in the growth of a leading innovator without the need for a margin account. ZYN seeks to deliver daily investment results, before fees and expenses, of 200% of the daily performance of Philip Morris International Inc.. The Fund utilizes derivatives such as swaps and options to achieve its leveraged objectives, offering prec

    9/4/25 9:59:28 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Participates in 2025 Barclays Global Consumer Staples Conference

    Reaffirms 2025 Full-Year Forecast for Reported Diluted EPS of $7.24 to $7.37 and Adjusted Diluted EPS of $7.43 to $7.56, Representing Growth of 13% to 15%, 11.5% to 13.5% Excluding Currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) Chief Executive Officer, Jacek Olczak, will address investors today at the 2025 Barclays Global Consumer Staples Conference. "With strong volume momentum over the summer months, including IQOS and ZYN offtake, and despite increasing competition in smoke-free products, we are on track to deliver our full-year guidance of 13% to 15% adjusted diluted EPS growth in dollar terms, the strongest since 2011 excluding the pandemic recovery,"

    9/2/25 9:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International to Host Webcast of Fireside Chat Session at Barclays Global Consumer Staples Conference

    Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live webcast of a fireside chat session with Jacek Olczak, Chief Executive Officer, at the 2025 Barclays Global Consumer Staples Conference at www.pmi.com/2025barclays on Tuesday, September 2, 2025, at approximately 11:15 a.m. ET. An archived copy of the webcast will be available for six months post-event. The webcast may also be accessed on mobile devices by downloading PMI's free Investor Relations Mobile App at www.pmi.com/irapp. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future

    8/26/25 8:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Trumpaitis Mindaugas claimed ownership of 73,002 shares (SEC Form 3)

    3 - Philip Morris International Inc. (0001413329) (Issuer)

    6/9/25 3:34:30 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Temperley Dessislava was granted 1,002 shares, increasing direct ownership by 15% to 7,756 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/9/25 4:54:43 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Bough Bonin was granted 1,002 shares, increasing direct ownership by 11% to 9,834 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/9/25 4:54:34 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    SEC Filings

    View All

    Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    9/2/25 9:04:47 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 25-NSE filed by Philip Morris International Inc

    25-NSE - Philip Morris International Inc. (0001413329) (Subject)

    8/11/25 9:57:45 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Philip Morris International Inc

    10-Q - Philip Morris International Inc. (0001413329) (Filer)

    7/25/25 8:11:01 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Financials

    Live finance-specific insights

    View All

    Philip Morris International Reports 2025 Second Quarter & First Six-Months Results and Raises Full-Year Guidance; Second Quarter Reported Diluted EPS Grew 26.6% to $1.95, Adjusted Diluted EPS Grew 20.1% to $1.91, and by 18.9% excluding currency

    Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 second quarter results.1 "Our business delivered very strong results in the second quarter, with record net revenues and exceptional growth in operating income and adjusted diluted EPS," said Jacek Olczak, Chief Executive Officer. "These results reflect excellent momentum in our multicategory smoke-free business, with a reacceleration of IQOS adjusted in-market sales growth and ZYN U.S. offtake growth, coupled with combustibles resilience. Given our strong year-to-date performance, we are raising our full-year guidance." _____________________________ 1 Explanation of PMI's use of non-GAAP me

    7/22/25 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Declares Regular Quarterly Dividend of $1.35 Per Share

    Regulatory News: The Board of Directors of Philip Morris International Inc. (PMI) (NYSE:PM) today declared a regular quarterly dividend of $1.35 per common share, payable on July 15, 2025, to shareholders of record as of June 27, 2025. The ex-dividend date is June 27, 2025. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primar

    6/13/25 5:45:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Participates in dbAccess Global Consumer Conference

    Reaffirms 2025 Full-Year Forecast for Reported Diluted EPS of $7.01 to $7.14 and Adjusted Diluted EPS of $7.36 to $7.49, Representing Growth of 12% to 14%, 10.5% to 12.5% Excluding Currency Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2025 dbAccess Global Consumer Conference in Paris. The event will be webcast live in listen-only mode, beginning at approximately 11:15 a.m. CEST (5:15 a.m. EST), at www.pmi.com/2025dbaccess and on the PMI Investor Relations Mobile Application (www.pmi.com/irapp). An archived copy of the webcast will be available for approximately one year. 2025 Full-Ye

    6/3/25 1:30:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $PM
    Leadership Updates

    Live Leadership Updates

    View All

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:21:26 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:05:54 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    1/29/24 3:26:29 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

    Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

    9/17/24 9:11:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Names New External Affairs Leader

    Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

    3/26/24 5:48:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International's U.S. Business Champions Female Economic Growth in Connecticut with Record-Setting $5 Million Investment Through New Partnership with Women's Business Development Council

    In honor of Women's History Month and in advance of International Women's Day, investment and partnership support female economic empowerment and equality through entrepreneurship Today, Philip Morris International (PMI) (NYSE:PM) announces the launch of an extended partnership via its U.S. business to support female empowerment with a record-setting $5 million investment in the Women's Business Development Council (WBDC), a 501(c)(3) charitable organization dedicated to providing tools and resources to help women entrepreneurs thrive in business throughout Connecticut. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202403048002

    3/4/24 6:48:00 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care